The Real-world Treatment Satisfaction by Gefapixiant in RCC

Launched by NAGOYA CITY UNIVERSITY · Aug 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a medication called gefapixant, which is designed to help people with chronic cough that doesn't improve with other treatments. Chronic cough can be very common and affects many people, but about 20% of patients find that other medications don't work for them. The researchers want to understand how gefapixant affects treatment satisfaction, especially since some patients may experience a change in taste—this happens in about 60-70% of those taking the medication. They think that even if patients notice a change in taste, it could still lead to better cough relief and overall satisfaction with the treatment.

To be eligible for this trial, participants should be adults aged 65 and older who have had a chronic cough for at least 8 weeks and have not found relief from other treatments. It's important that they are either non-smokers or have a limited smoking history (20 cigarettes per day or less). However, individuals with certain lung diseases, current smokers, or those who are pregnant cannot participate. If you join the trial, you'll be part of a study that aims to improve understanding and treatment options for chronic cough, and you may gain access to a potential new therapy designed to help manage your symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult patients with RCC and UCC (8 weeks or more).
• • 2. Cough is refractory to intensive specific treatments for causes of chronic cough.
• • 3. Never smokers and ex-smokers with having smoking history of ≤20 pack-years.
• Exclusion Criteria:
• • 1. Patients with lung cancer, interstitial lung diseases, bronchiectasis, or respiratory infection such as tuberculosis and acute pneumonia.
• • 2. Current smoker, ex-smokers with having smoking history of \>20 pack-years, or those who quit smoking within six months prior to receiving gefapixant.
• • 3. Those who are pregnant.